L C Swayne
Overview
Explore the profile of L C Swayne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jacobs I, Chevinsky A, Swayne L, Magidson J, Britto E, Smith T
J Surg Oncol
. 2001 Jul;
77(3):157-64.
PMID: 11455551
Background And Objectives: Some patients presenting with cutaneous malignant melanoma without palpable adenopathy have regional metastatic disease. The results of a prospective clinical study of gamma probe-directed sentinel lymph node...
2.
Juweid M, Hajjar G, Stein R, Sharkey R, HERSKOVIC T, Swayne L, et al.
J Nucl Med
. 2000 Jan;
41(1):93-103.
PMID: 10647610
Unlabelled: This phase I study was initiated to determine the toxicity and therapeutic potential of high-dose 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody (MAb) combined with autologous hematopoietic stem cell rescue...
3.
Juweid M, Stadtmauer E, Hajjar G, Sharkey R, Suleiman S, Luger S, et al.
Clin Cancer Res
. 1999 Oct;
5(10 Suppl):3292s-3303s.
PMID: 10541378
The pharmacokinetics, dosimetry, and immunogenicity of 131I- and (111)In-/90Y-humanized LL2 (hLL2) anti-CD22 monoclonal antibodies were determined in patients with recurrent non-Hodgkin's lymphoma. Fourteen patients received tracer doses of 131I-hLL2 followed...
4.
Juweid M, Hajjar G, Swayne L, Sharkey R, Suleiman S, HERSKOVIC T, et al.
Cancer
. 1999 May;
85(8):1828-42.
PMID: 10223579
Background: Monoclonal antibodies (MAbs) against carcinoembryonic antigen (CEA) have been recognized as targeting agents for medullary thyroid carcinoma (MTC). This Phase I/II study was initiated to determine the safety, maximum...
5.
Juweid M, Sharkey R, Swayne L, Griffiths G, Dunn R, Goldenberg D
J Nucl Med
. 1998 Jan;
39(1):34-42.
PMID: 9443735
Unlabelled: The biodistribution, pharmacokinetics and dosimetry of 188Re-labeled MN-14, an IgG anti-carcinoembryonic antigen monoclonal antibody (MAb), were assessed in patients in advanced gastrointestinal cancer. In addition, the dose-limiting toxicity (DLT)...
6.
Juweid M, Swayne L, Sharkey R, Dunn R, Rubin A, HERSKOVIC T, et al.
Gynecol Oncol
. 1998 Jan;
67(3):259-71.
PMID: 9441773
Objectives: Epithelial ovarian cancer (EOC) is known to produce carcinoembryonic antigen (CEA), and the plasma CEA level is frequently elevated in patients with advanced stage and bulk of tumor. This...
7.
Juweid M, Sharkey R, Swayne L, Goldenberg D
Surgery
. 1998 Jan;
122(6):1156-65.
PMID: 9426433
Background: This study examined the utility of using radiolabeled anticarcinoembryonic antigen (CEA) monoclonal antibodies (MAbs) as a noninvasive imaging method to aid in the selection of patients for reoperation after...
8.
Behr T, Sharkey R, Juweid M, Dunn R, Vagg R, Ying Z, et al.
J Nucl Med
. 1997 Jun;
38(6):858-70.
PMID: 9189130
Unlabelled: The aim of this study was to determine, in a Phase I/II clinical trial, the pharmacokinetics, dosimetry and toxicity, as well as antitumor activity, of the 131I-labeled murine anti-carcinoembryonic...
9.
Juweid M, Sharkey R, Alavi A, Swayne L, HERSKOVIC T, Hanley D, et al.
J Nucl Med
. 1997 Feb;
38(2):257-60.
PMID: 9025751
Advanced chemotherapy-resistant ovarian cancer has a poor prognosis, thus requiring new therapeutic modalities. A complete clinical remission, using two cycles of 131I-labeled murine MN-14 anti-CEA monoclonal antibody (MAb), given intravenously,...
10.
Schwartz M, Swayne L, Macaulay R, Schwartz J
J Nucl Med
. 1996 Nov;
37(11):1826-7.
PMID: 8917184
We present a case of visualization of a clot in the superior vena cava with collateral flow to the liver during a lung perfusion scan. A digital venogram performed after...